98%
921
2 minutes
20
Objectives: We characterized real-time patient portal test result viewing among emergency department (ED) patients and described patient characteristics overall and among those not enrolled in the portal at ED arrival.
Methods: Our observational study at an academic ED used portal log data to trend the proportion of adult patients who viewed results during their visit from May 04, 2021 to April 04, 2022. Correlation was assessed visually and with Kendall's τ. Covariate analysis using binary logistic regression assessed as a function of time accounting for age, sex, ethnicity, race, language, insurance status, disposition, and social vulnerability index (SVI). A second model only included patients not enrolled in the portal at arrival. We used random forest imputation to account for missingness and Huber-White heteroskedasticity-robust standard errors for patients with multiple encounters ( = 0.05).
Results: There were 60,314 ED encounters (31,164 unique patients). In 7,377 (12.2%) encounters, patients viewed results while still in the ED. Patients were not enrolled for portal use at arrival in 21,158 (35.2%) encounters, and 927 (4.4% of not enrolled, 1.5% overall) subsequently enrolled and viewed results in the ED. Visual inspection suggests an increasing proportion of patients who viewed results from roughly 5 to 15% over the study (Kendall's τ = 0.61 [ <0.0001]). Overall and not-enrolled models yielded concordance indices () of 0.68 and 0.72, respectively, with significant overall likelihood ratio ( <0.0001). Time was independently associated with viewing results in both models after adjustment. Models revealed disparate use between age, race, ethnicity, SVI, sex, insurance status, and disposition groups.
Conclusion: We observed increased portal-based test result viewing among ED patients over the year since the 21 Century Cures act went into effect, even among those not enrolled at arrival. We observed disparities in those who viewed results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713300 | PMC |
http://dx.doi.org/10.1055/a-1951-3268 | DOI Listing |
Front Public Health
September 2025
Department of Medicine, University of Chicago, Chicago, IL, United States.
Background: Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S) is a research project funded by the National Institute for Drug Abuse to implement and evaluate multi-level interventions to decrease barriers to substance use screening and treatment for PLWH. At its center is a multidomain intervention addressing digital, sociocultural, and health care system environments, at individual, interpersonal, and community levels. ePORTAL HIV-S has four overall goals; this manuscript describes the protocol specifically for the randomized control trial (RCT) portion of the study.
View Article and Find Full Text PDFRheumatol Adv Pract
July 2025
Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
Objective: Lack of timely referral of suspected axial spondyloarthritis (axSpA) patients to rheumatologists is an important modifiable reason for diagnostic delay of axSpA. We assessed the usefulness of a self-referral strategy using a clinical feature-based screening questionnaire (SQ) (A-tool).
Methods: Finding axSpA (FaxSpA) was single-centre prospective study involving patients with chronic back pain (CBP).
World J Hepatol
August 2025
Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Background: Clinically significant portal hypertension (CSPH) is a crucial prognostic determinant for liver-related events (LREs) in patients with compensated viral cirrhosis. Liver stiffness measurement (LSM)-related markers may help to predict the risk of LREs.
Aim: To evaluate the value of LSM and its composite biomarkers [LSM-platelet ratio (LPR), LSM-albumin ratio (LAR)] in predicting LREs.
Lancet
August 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Background: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subsequent VICTOR trial evaluated the use of vericiguat in patients with HFrEF and no recent worsening. We aimed to assess the effect of vericiguat on clinical endpoints through pooled analyses of patient-level data from the VICTORIA and VICTOR trials.
View Article and Find Full Text PDFEClinicalMedicine
September 2025
Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Rebleeding after initial endoscopic therapy is associated with high mortality in patients with hepatitis B virus (HBV)-related liver cirrhosis complicated by esophagogastric variceal bleeding (EGVB), imposing a substantial public health burden. Spontaneous portosystemic shunts (SPSS), a compensatory mechanism for portal hypertension, are closely associated with disease progression. This study aimed to develop and validate machine learning (ML) models incorporating clinical and imaging features to predict the risk and frequency of rebleeding following initial endoscopic treatment.
View Article and Find Full Text PDF